These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 18804176)

  • 1. Macrolide myths.
    Mankin AS
    Curr Opin Microbiol; 2008 Oct; 11(5):414-21. PubMed ID: 18804176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrolide antibiotics in the ribosome exit tunnel: species-specific binding and action.
    Kannan K; Mankin AS
    Ann N Y Acad Sci; 2011 Dec; 1241():33-47. PubMed ID: 22191525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Ribosomal antibiotics].
    Man'kin AS
    Mol Biol (Mosk); 2001; 35(4):597-609. PubMed ID: 11524946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrolide antibiotics: binding site, mechanism of action, resistance.
    Gaynor M; Mankin AS
    Curr Top Med Chem; 2003; 3(9):949-61. PubMed ID: 12678831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective protein synthesis by ribosomes with a drug-obstructed exit tunnel.
    Kannan K; Vázquez-Laslop N; Mankin AS
    Cell; 2012 Oct; 151(3):508-20. PubMed ID: 23101624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrolide antibiotic interaction and resistance on the bacterial ribosome.
    Poehlsgaard J; Douthwaite S
    Curr Opin Investig Drugs; 2003 Feb; 4(2):140-8. PubMed ID: 12669373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis.
    Llano-Sotelo B; Dunkle J; Klepacki D; Zhang W; Fernandes P; Cate JH; Mankin AS
    Antimicrob Agents Chemother; 2010 Dec; 54(12):4961-70. PubMed ID: 20855725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bacterial ribosome as a target for antibiotics.
    Poehlsgaard J; Douthwaite S
    Nat Rev Microbiol; 2005 Nov; 3(11):870-81. PubMed ID: 16261170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the evolution of macrolides resistance: A mini review.
    Nor Amdan NA; Shahrulzamri NA; Hashim R; Mohamad Jamil N
    J Glob Antimicrob Resist; 2024 Sep; 38():368-375. PubMed ID: 39117142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Context-specific action of macrolide antibiotics on the eukaryotic ribosome.
    Svetlov MS; Koller TO; Meydan S; Shankar V; Klepacki D; Polacek N; Guydosh NR; Vázquez-Laslop N; Wilson DN; Mankin AS
    Nat Commun; 2021 May; 12(1):2803. PubMed ID: 33990576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural consideration of macrolide antibiotics in relation to the ribosomal interaction and drug design.
    Takashima H
    Curr Top Med Chem; 2003; 3(9):991-9. PubMed ID: 12678833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The macrolide-bacterium interaction and its biological basis.
    Goldman RC; Scaglione F
    Curr Drug Targets Infect Disord; 2004 Sep; 4(3):241-60. PubMed ID: 15379734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the mechanism of action of 9-O-arylalkyloxime derivatives of 6-O-mycaminosyltylonolide, a new class of 16-membered macrolide antibiotics.
    Karahalios P; Kalpaxis DL; Fu H; Katz L; Wilson DN; Dinos GP
    Mol Pharmacol; 2006 Oct; 70(4):1271-80. PubMed ID: 16873579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding site of macrolide antibiotics on the ribosome: new resistance mutation identifies a specific interaction of ketolides with rRNA.
    Garza-Ramos G; Xiong L; Zhong P; Mankin A
    J Bacteriol; 2001 Dec; 183(23):6898-907. PubMed ID: 11698379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interplay between the ribosomal tunnel, nascent chain, and macrolides influences drug inhibition.
    Starosta AL; Karpenko VV; Shishkina AV; Mikolajka A; Sumbatyan NV; Schluenzen F; Korshunova GA; Bogdanov AA; Wilson DN
    Chem Biol; 2010 May; 17(5):504-14. PubMed ID: 20534348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrolide antibiotics allosterically predispose the ribosome for translation arrest.
    Sothiselvam S; Liu B; Han W; Ramu H; Klepacki D; Atkinson GC; Brauer A; Remm M; Tenson T; Schulten K; Vázquez-Laslop N; Mankin AS
    Proc Natl Acad Sci U S A; 2014 Jul; 111(27):9804-9. PubMed ID: 24961372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The macrolide binding site on the bacterial ribosome.
    Poehlsgaard J; Douthwaite S
    Curr Drug Targets Infect Disord; 2002 Mar; 2(1):67-78. PubMed ID: 12462154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of drug-ribosome interactions defines the cidality of macrolide antibiotics.
    Svetlov MS; Vázquez-Laslop N; Mankin AS
    Proc Natl Acad Sci U S A; 2017 Dec; 114(52):13673-13678. PubMed ID: 29229833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blast from the Past: Reassessing Forgotten Translation Inhibitors, Antibiotic Selectivity, and Resistance Mechanisms to Aid Drug Development.
    Arenz S; Wilson DN
    Mol Cell; 2016 Jan; 61(1):3-14. PubMed ID: 26585390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The structural basis of macrolide-ribosome binding assessed using mutagenesis of 23S rRNA positions 2058 and 2059.
    Pfister P; Jenni S; Poehlsgaard J; Thomas A; Douthwaite S; Ban N; Böttger EC
    J Mol Biol; 2004 Oct; 342(5):1569-81. PubMed ID: 15364582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.